169 related articles for article (PubMed ID: 30693666)
21. Is preoperative serum prostate-specific antigen level significantly related to clinical recurrence after radical retropubic prostatectomy for localized prostate cancer?
Haukaas SA; Halvorsen OJ; Daehlin L; Hostmark J; Akslen LA
BJU Int; 2006 Jan; 97(1):51-5. PubMed ID: 16336328
[TBL] [Abstract][Full Text] [Related]
22. Impact of the EpCAM expression on biochemical recurrence-free survival in clinically localized prostate cancer.
Benko G; Spajić B; Krušlin B; Tomas D
Urol Oncol; 2013 May; 31(4):468-74. PubMed ID: 21514185
[TBL] [Abstract][Full Text] [Related]
23. Neutrophil-to-lymphocyte ratio predicts progression and recurrence of non-muscle-invasive bladder cancer.
Mano R; Baniel J; Shoshany O; Margel D; Bar-On T; Nativ O; Rubinstein J; Halachmi S
Urol Oncol; 2015 Feb; 33(2):67.e1-7. PubMed ID: 25060672
[TBL] [Abstract][Full Text] [Related]
24. Impact of Gleason pattern 5 including tertiary pattern 5 on outcomes of salvage treatment for biochemical recurrence in pT2-3N0M0 prostate cancer.
Taguchi S; Shiraishi K; Fukuhara H; Nakagawa K; Morikawa T; Naito A; Kakutani S; Takeshima Y; Miyazaki H; Nakagawa T; Fujimura T; Kume H; Homma Y
Int J Clin Oncol; 2016 Oct; 21(5):975-980. PubMed ID: 27098807
[TBL] [Abstract][Full Text] [Related]
25. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.
Kupelian PA; Katcher J; Levin HS; Klein EA
Int J Radiat Oncol Biol Phys; 1997 Mar; 37(5):1043-52. PubMed ID: 9169811
[TBL] [Abstract][Full Text] [Related]
26. Association of ERG/PTEN status with biochemical recurrence after radical prostatectomy for clinically localized prostate cancer.
Mehra R; Salami SS; Lonigro R; Bhalla R; Siddiqui J; Cao X; Spratt DE; Palapattu GS; Palanisamy N; Wei JT; Chinnaiyan AM; Tomlins SA
Med Oncol; 2018 Oct; 35(12):152. PubMed ID: 30291535
[TBL] [Abstract][Full Text] [Related]
27. Importance of tumor location in patients with high preoperative prostate specific antigen levels (greater than 20 ng/ml) treated with radical prostatectomy.
Magheli A; Rais-Bahrami S; Peck HJ; Walsh PC; Epstein JI; Trock BJ; Gonzalgo ML
J Urol; 2007 Oct; 178(4 Pt 1):1311-5. PubMed ID: 17698095
[TBL] [Abstract][Full Text] [Related]
28. Neutrophil, lymphocyte and platelet counts, and risk of prostate cancer outcomes in white and black men: results from the SEARCH database.
Vidal AC; Howard LE; de Hoedt A; Cooperberg MR; Kane CJ; Aronson WJ; Terris MK; Amling CL; Taioli E; Fowke JH; Freedland SJ
Cancer Causes Control; 2018 Jun; 29(6):581-588. PubMed ID: 29663110
[TBL] [Abstract][Full Text] [Related]
29. The factors predicting biochemical recurrence in patients with radical prostatectomy.
Koca O; Ün S; Türk H; Zorlu F
Arch Ital Urol Androl; 2016 Jan; 87(4):270-5. PubMed ID: 26766796
[TBL] [Abstract][Full Text] [Related]
30. The Impact of Downgrading from Biopsy Gleason 7 to Prostatectomy Gleason 6 on Biochemical Recurrence and Prostate Cancer Specific Mortality.
Ham WS; Chalfin HJ; Feng Z; Trock BJ; Epstein JI; Cheung C; Humphreys E; Partin AW; Han M
J Urol; 2017 Apr; 197(4):1060-1067. PubMed ID: 27847296
[TBL] [Abstract][Full Text] [Related]
31. Clinical value of cholinesterase in the prediction of biochemical recurrence after radical prostatectomy.
D'Andrea D; Soria F; Abufaraj M; Gust K; Foerster B; Vartolomei MD; Kimura S; Mari A; Briganti A; Remzi M; Seitz CK; Mathieu R; Karakiewicz PI; Shariat SF
Urol Oncol; 2018 Dec; 36(12):528.e7-528.e13. PubMed ID: 30446461
[TBL] [Abstract][Full Text] [Related]
32. Preoperative predictive factors and further risk stratification of biochemical recurrence in clinically localized high-risk prostate cancer.
Hamada R; Nakashima J; Ohori M; Ohno Y; Komori O; Yoshioka K; Tachibana M
Int J Clin Oncol; 2016 Jun; 21(3):595-600. PubMed ID: 26585896
[TBL] [Abstract][Full Text] [Related]
33. Patterns and predictors of early biochemical recurrence after radical prostatectomy and adjuvant radiation therapy in men with pT3N0 prostate cancer: implications for multimodal therapies.
Briganti A; Joniau S; Gandaglia G; Cozzarini C; Sun M; Tombal B; Haustermans K; Hinkelbein W; Shariat SF; Karakiewicz PI; Montorsi F; Van Poppel H; Wiegel T
Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):960-7. PubMed ID: 24351411
[TBL] [Abstract][Full Text] [Related]
34. Prognostic Role of Preoperative Serum Lipid Levels in Patients Undergoing Radical Prostatectomy for Clinically Localized Prostate Cancer.
Wettstein MS; Saba K; Umbehr MH; Murtola TJ; Fankhauser CD; Adank JP; Hofmann M; Sulser T; Hermanns T; Moch H; Wild P; Poyet C
Prostate; 2017 Apr; 77(5):549-556. PubMed ID: 28093792
[TBL] [Abstract][Full Text] [Related]
35. High pretreatment neutrophil-lymphocyte ratio predicts recurrence and poor prognosis for combined small cell lung cancer.
Shao N; Cai Q
Clin Transl Oncol; 2015 Oct; 17(10):772-8. PubMed ID: 26243392
[TBL] [Abstract][Full Text] [Related]
36. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
[TBL] [Abstract][Full Text] [Related]
37. Is neutrophile to lymphocyte ratio a predictor of Gleason score upgrading according to risk classifications in patients with prostate cancer.
Karadağ S; Ekşi M; Özdemir O; Akkaş F; Arikan Y; Özlü DN; Çolakoğlu Y; Aliş D; Şahin S; Tuğcu V
Arch Esp Urol; 2021 Jul; 74(6):599-605. PubMed ID: 34219063
[TBL] [Abstract][Full Text] [Related]
38. Testosterone as a predictor of pathological stage in clinically localized prostate cancer.
Isom-Batz G; Bianco FJ; Kattan MW; Mulhall JP; Lilja H; Eastham JA
J Urol; 2005 Jun; 173(6):1935-7. PubMed ID: 15879785
[TBL] [Abstract][Full Text] [Related]
39. High level of androgen receptor is associated with aggressive clinicopathologic features and decreased biochemical recurrence-free survival in prostate: cancer patients treated with radical prostatectomy.
Li R; Wheeler T; Dai H; Frolov A; Thompson T; Ayala G
Am J Surg Pathol; 2004 Jul; 28(7):928-34. PubMed ID: 15223964
[TBL] [Abstract][Full Text] [Related]
40. Pretreatment Neutrophil to Lymphocyte Ratio Is Associated with Poor Survival in Patients with Stage I-III Non-Small Cell Lung Cancer.
Wang J; Kalhor N; Hu J; Wang B; Chu H; Zhang B; Guan Y; Wu Y
PLoS One; 2016; 11(10):e0163397. PubMed ID: 27695079
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
